We report the diagnosis and treatment of patients with retinal detachment and/or retinoschisis associated with optic nerve coloboma or morning glory syndrome. A retrospective review of patients ...

It will grow to $2.98 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. ” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, May 28, 2025 /EINPresswire.com/ -- The ...

Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease ...

Hamza Mussa, lead optometrist at Specsavers Banbury, and patient, Emma Williams, on a referral for a retinal tear ...

Digital device use and reading distance are linked to changes in choroidal thickness among Tokyo children. The study finds ...

Discover why Type 2 diabetes progression remains undetectable. Learn 8 silent processes that damage your body without warning signs or symptoms.

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...

Retinal drugs market growth driven by aging population, rising AMD prevalence, and advances in ophthalmic drug delivery and retinal disease treatment innovation.